

Edgar Filing: CYTOGEN CORP - Form 8-K/A

CYTOGEN CORP  
Form 8-K/A  
April 26, 2006

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

-----  
FORM 8-K/A

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 20, 2006  
-----

CYTOGEN CORPORATION

-----  
(Exact Name of Registrant as Specified in Charter)

Delaware	000-14879	22-2322400
----- (State or Other Jurisdiction of Incorporation)	----- (Commission File Number)	----- (I.R.S. Employer Identification No.)
650 College Road East, CN 5308, Suite 3100, Princeton, NJ		08540
----- (Address of Principal Executive Offices)		----- (Zip Code)

Registrant's telephone number, including area code: (609) 750-8200  
-----

-----  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: CYTOGEN CORP - Form 8-K/A

### ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS

This Form 8-K/A amends the Form 8-K filed by Cytogen Corporation (the "Company") on April 26, 2006 with respect to the sale by the Company to Progenics Pharmaceuticals, Inc. ("Progenics") of the Company's 50% ownership interest in PSMA Development Company LLC (the "Joint Venture"). On April 20, 2006, the Company entered into a Membership Interest Purchase Agreement with Progenics providing for the sale to Progenics of the Company's 50% ownership interest in the Joint Venture. In addition, the Company entered into an Amended and Restated PSMA/PSMP License Agreement with Progenics and the Joint Venture pursuant to which the Company licensed the Joint Venture certain rights in PSMA technology. Under the terms of such agreements, the Company sold its 50% interest in the Joint Venture for an upfront cash payment of \$13.2 million, potential future milestone payments totaling up to \$52 million payable upon regulatory approval and commercialization of the Joint Venture products, and an undisclosed royalty on future product sales of the Joint Venture.

The following unaudited pro forma balance sheet information of the Company reflects the disposition of the Joint Venture as if it had occurred on December 31, 2005. The accompanying unaudited pro forma statements of operations information for the years ended December 31, 2005, 2004 and 2003, reflect the disposition of the Joint Venture as if the sale had occurred on January 1, 2003. The pro forma adjustments are based on the operations of the Joint Venture during the periods presented and the impact from the sale of the Joint Venture. Consequently, the pro forma financial information presented is not necessarily indicative of the results that would have been reported had the transactions actually occurred on the dates specified. The pro forma adjustments do not include any gains the Company may record in connection with this transaction.

The pro forma adjustments for the years ended December 31, 2005, 2004 and 2003, from the sale of the Company's 50% ownership interest in the Joint Venture would have reduced license and contract revenue by \$185,000, \$106,000 and \$214,000, respectively, equity in loss of Joint Venture by \$3.2 million, \$2.9 million, and \$3.5 million, respectively, and Loss from Continuing Operations by \$3.0 million, \$2.8 million and \$3.2 million, respectively, or \$0.17, \$0.19 and \$0.32 per basic and diluted share. In addition, the pro forma adjustments as of December 31, 2005 from the sale of the Company's 50% ownership interest in the Joint Venture would have increased cash and cash equivalents by \$3.8 million, and reduced other Assets by \$775,000 and Accumulated Deficit by \$3.0 million.

The unaudited pro forma condensed balance sheet and Statements of Operations information reflect the historical financial information adjusted for the pro forma adjustments discussed above:

CYTOGEN CORPORATION AND SUBSIDIARIES  
PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEETS  
AS OF DECEMBER 31, 2005  
(All amounts in thousands, except share and per share data)  
(Unaudited)

December 31,  
2005  
-----

Edgar Filing: CYTOGEN CORP - Form 8-K/A

ASSETS:

Current assets:

Cash and cash equivalents.....	\$	34,102
Accounts receivable, net.....		1,743
Inventories.....		3,582
Property and equipment, net.....		886
Quadramet license fee, net.....		6,327
Other assets.....		1,140
		-----
	\$	47,780
		-----

LIABILITIES AND STOCKHOLDERS' EQUITY:

Accounts payable and accrued liabilities.....		5,271
Warrant liability.....		1,869
Other liabilities.....		72
		-----
Total liabilities.....		7,212
		-----

Commitments and contingencies

Stockholders' equity:

Preferred stock, \$.01 par value, 5,400,000 shares authorized - Series C Junior Participating Preferred Stock, \$.01 par value, 200,000 shares authorized, none issued and outstanding.....		--
Common stock, \$.01 par value, 50,000,000 shares authorized, 22,473,762 and 15,489,116 shares issued and outstanding at December 31, 2005 and December 31, 2004, respectively.....		225
Additional paid-in capital.....		450,502
Unearned compensation.....		(610)
Accumulated other comprehensive income.....		28
Accumulated deficit.....		(409,577)
		-----
Total stockholders' equity.....		40,568
		-----
	\$	47,780
		-----

CYTOGEN CORPORATION AND SUBSIDIARIES  
 PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
 (All amounts in thousands, except share and per share data)  
 (Unaudited)

Year Ende  
 2005 2

Edgar Filing: CYTOGEN CORP - Form 8-K/A

REVENUES:

Product related:			
PROTASCINT.....	\$	7,407	\$
QUADRAMET.....		8,350	
NMP22 BLADDERCHEK.....		--	
BRACHYSEED.....		--	
		=====	=====
Total product revenues.....		15,757	1
QUADRAMET royalties.....		--	
		=====	=====
Total product related revenues.....		15,757	1
License and contract.....		4	
		=====	=====
Total revenues.....		15,761	1
		=====	=====
OPERATING EXPENSES:			
Cost of product related revenues.....		9,621	
Selling, general and administrative.....		25,895	2
Research and development.....		6,064	
Equity in loss of joint venture.....		--	
Impairment of intangible assets.....		--	
		=====	=====
Total operating expenses.....		41,580	3
		=====	=====
Loss from continuing operations.....		(25,819)	(1)
Interest income.....		712	
Interest expense.....		(114)	
Decrease in value of warrant liability.....		1,666	
		=====	=====
Loss before income taxes.....		(23,555)	(1)
Income tax benefit.....		(256)	
		=====	=====
Net loss.....	\$	(23,299)	\$ (1)
		=====	=====
Basic and diluted net loss per share.....	\$	(1.36)	\$
		=====	=====
Weighted-average common shares outstanding.....		17,117	1
		=====	=====

SIGNATURES

Edgar Filing: CYTOGEN CORP - Form 8-K/A

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CYTOGEN CORPORATION

By: /s/ Michael D. Becker

-----  
Michael D. Becker  
President and Chief Executive Officer

Dated: April 26, 2006